SmartStream Launch the Latest Version of TLM Reconciliations Premium to Enable User Independence and Operational Flexibility
16.10.2017 11:00:00 EEST | Business Wire | Press release
SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announced the launch of its latest reconciliations solution. The third major release of its TLM Reconciliations Premium solution comes with a range of services to meet customer requirements for a flexible self-service user experience, comprehensive trend analysis for match rate optimisation and exception reduction, and model choices for each reconciliation – allowing customers to easily shape and form the solution in an innovative way, whilst optimising costs and operational overhead.
The latest release continues SmartStream’s investment in providing a wide-ranging reconciliation solution, delivering additional business benefits at every stage of the lifecycle. A new feature, TLM View, provides a flexible, user driven approach to analytics, with no reliance on IT support, allowing access to the full range of real-time and historic data in the reconciliation repository – this will help identify trends and exception patterns to further reduce manual intervention. TLM View also delivers full operational functionality in one single interface, driven by flexible dashboards and fully customisable by business users.
Another key element of the latest release is TLM SmartRecs, SmartStream’s rapid onboarding and automated match rule creation solution – which now has further features, including data transformation functions and enhanced analysis of incoming data. TLM SmartRecs allows business users to independently model new reconciliations or fine-tune existing reconciliations to improve outcomes.
Rocky Martinez, CTO, SmartStream, states: “With the latest release of TLM Reconciliations Premium we have the infrastructure to allow for robotic process automation (RPA) and have the ability to view distributed ledger information. This is what we view as the future as it becomes industry standard for our customers.”
TLM Reconciliations Premium now provides a choice in how each reconciliation is persisted, TLM Persist offers alternatives that range from a supported relational database management system (RDBMS) to lighter storage options. Regardless of persistence choice, all reconciliations can be accessed through the same user interface, which allows the management of costs and operational overheads, without the need to compromise on user experience.
It has already been in testing with customers and feedback has been positive for the solution which has high operational excellence, scalability and ease of deployment - customers find the solution easy to use and can expect to realise the benefits within the calendar year.
Haytham Kaddoura, CEO, SmartStream, commented; “This major release positions SmartStream with a unique offering, rather than relying on multiple vendors to provide a range of services, we provide a complete and comprehensive package with enhanced features and functionality already built-in. As the first software/service provider to offer an industry-led, purpose-built utility, this new version of our award winning TLM Reconciliations Premium solution is the result of what we have learned over the years combined with what our customers have asked for, creating something unmatched in the marketplace.”
Ends
About SmartStream Technologies
SmartStream Technologies is
a recognised leader in financial transaction management software that
enables firms to overcome critical transaction processing issues through
increased automation.
SmartStream’s industry-leading automated match rates create more proactive, exceptions-based processes that lower the cost per transaction while enabling firms to reduce operational risk, strengthen compliance and controls, and improve customer service.
As a result, more than 1,500 clients, including 75 of the world’s top 100 banks, 8 of the top 10 asset managers, and 8 of the top 10 custodians rely on SmartStream Transaction Lifecycle Management (TLM®) solutions to deliver greater efficiency to their trading operations.
For more information about SmartStream visit: www.smartstream-stp.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171016005170/en/
Contact information
Dina Communications
Shamira Alidina
Media Relations
Director
Tel +44 (0) 7801 590718
Email: shamira@dinacomms.com
or
SmartStream
Technologies
Nathan Gee
Senior Marketing Manager
Tel:
+44 (0) 20 7898 0630
Email: nathan.gee@smartstream-stp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom